Advertisement HDS, DS Healthcare enter agreement to launch Clotamin in UK - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

HDS, DS Healthcare enter agreement to launch Clotamin in UK

Sunpeaks Ventures' wholly owned subsidiary, Healthcare Distribution Specialists (HDS), has entered into an agreement with DS Healthcare to introduce Clotamin into the UK and other European Union markets.

Clotamin is an over-the-counter multivitamin product designed for use by patients on Warfarin or other anticoagulants (blood thinners).

Under terms of the agreement, DS Healthcare will evaluate the Clotamin formulation and claims against the European Union Food Supplement Directive, the Nutritional Health Claims Directive, and Food Labeling Regulations to determine any specific actions and timeline required to introduce Clotamin to the UK/EU market.

Sunpeaks Ventures CEO Mackie Barch said the company intends to fully utilize its technical, commercial, and regulatory expertise to build and launch the Clotamin brand across Europe.

Sunpeaks Ventures is a nationally focused, value-added distributor of specialty drugs and over-the-counter branded multivitamins to the healthcare provider market.